Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 4/20 | 0.62 |
| ▸ | CDK2 | P24941 | 4/20 | 0.62 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.62 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 13/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 3/20 | 0.52 |
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793005 | 0.86 | CCNA2 (0.65) | CCNA2CDK2CCNA1RAD52F10 | |
| SCHEMBL6791596 | 0.85 | CCNA2 (0.58) | CCNA2CDK2CCNA1AURKAIKBKB | |
| SCHEMBL11865536 | 0.81 | RAD52 (0.61) | CCNA2CDK2CCNA1RAD52IKBKB | |
| SCHEMBL11871559 | 0.80 | RAD52 (0.62) | CCNA2CDK2CCNA1RAD52IKBKB | |
| SCHEMBL6792816 | 0.79 | CCNA2 (0.55) | CCNA2CDK2CCNA1AURKA | |
| SCHEMBL23889148 | 0.79 | CCNA2 (0.57) | CCNA2CDK2CCNA1RAD52AURKA | |
| SCHEMBL11868715 | 0.79 | RAD52 (0.68) | CCNA2CDK2CCNA1RAD52 | |
| SCHEMBL6195933 | 0.78 | CCNA2 (0.55) | CCNA2CDK2CCNA1AURKAIKBKB | |
| SCHEMBL11867763 | 0.78 | RAD52 (0.70) | CCNA2CDK2CCNA1RAD52 | |
| SCHEMBL5227197 | 0.77 | CCNA2 (1.00) | CCNA2CDK2CCNA1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CCNA2 270/4885CDK2 29/4885CCNA1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.